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Abstract
Aims/hypothesis This meta-analysis aimed to compare the
renal outcomes between ACE inhibitor (ACEI)/angiotensin II
receptor blocker (ARB) and other antihypertensive drugs or
placebo in type 2 diabetes.
Methods Publications were identified from Medline and
Embase up to July 2011. Only randomised controlled trials
comparing ACEI/ARB monotherapy with other active drugs
or placebo were eligible. The outcome of end-stage renal
disease, doubling of serum creatinine, microvascular compli-
cations, microalbuminuria, macroalbuminuria and albumin-
uria regression were extracted. Risk ratios were pooled using
a random-effects model if heterogeneity was present; a fixed-
effects model was used in the absence of heterogeneity.
Results Of 673 studies identified, 28 were eligible (n013–
4,912). In direct meta-analysis, ACEI/ARB had significantly
lower risk of serum creatinine doubling (pooled RR00.66
[95% CI 0.52, 0.83]), macroalbuminuria (pooled RR00.70
[95% CI 0.50, 1.00]) and albuminuria regression (pooled RR
1.16 [95% CI 1.00, 1.39]) than other antihypertensive drugs,
mainly calcium channel blockers (CCBs). Although the risks
of end-stage renal disease and microalbuminuria were lower
intheACEI/ARBgroup (pooledRR0.82[95%CI 0.64,1.05]
and 0.84 [95% CI 0.61, 1.15], respectively), the differences
were not statistically significant. The ACEI/ARB benefit over
placebo was significant for all outcomes except microalbumi-
nuria. A network meta-analysis detected significant treatment
effects across all outcomes for both active drugs and placebo
comparisons.
Conclusions/interpretation Our review suggests a consistent
reno-protective effect of ACEI/ARB over other antihyperten-
sive drugs, mainly CCBs, and placebo in type 2 diabetes. The
lack of any differences in BP decrease between ACEI/ARB
and active comparators suggest this benefit is not due simply
to the antihypertensive effect.
Keywords Albuminuria regression.Angiotensin receptor
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Macroalbuminuria.Meta-analysis.Microalbuminuria.
Renin–angiotensin system blockade.Reno-protective
effect.Systematic review.Type 2 diabetes
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-011-2398-8) contains peer-reviewed but unedited
supplementary material, which is available to authorised users.
P. Vejakama:A. Thakkinstian (*):A. Ingsathit
Section for Clinical Epidemiology and Biostatistics,
Faculty of Medicine, Ramathibodi Hospital, Mahidol University,
Rama 6 Road, Rachatevi,
Bangkok 10400, Thailand
e-mail: raatk@mahidol.ac.th
P. Vejakama
Bundarik Hospital,
Ubon Ratchathani Province, Thailand
D. Lertrattananon
Department of Family Medicine, Faculty of Medicine,
Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
C. Ngarmukos
Division of Endocrinology and Metabolism,
Department of Medicine, Faculty of Medicine,
Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
J. Attia
Centre for Clinical Epidemiology and Biostatistics,
School of Medicine and Public Health,
University of Newcastle and Hunter Medical Research Institute,
Newcastle, NSW, Australia
Diabetologia (2012) 55:566–578
DOI 10.1007/s00125-011-2398-8Abbreviations
ACEI ACE inhibitor
ARB Angiotensin II receptor blocker
BB Beta-blocker
CCB Calcium-channel blocker
DBP Diastolic BP
d-CCB Dihydropyridine CCB
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Introduction
Diabetic nephropathy is a significant health and economic
burden across the world. The prevalence of micro- and
macroalbuminuria in type 2 diabetes is as high as 37–40%
in western countries and 57.4–59.8% in Asian countries [1–3].
Microalbuminuria is a well-established risk factor for car-
diovascular disease and is also associated with end-stage
renal disease (ESRD) [4–7]. Preventive treatments have
been prescribed for type 2 diabetes with or without hyper-
tension with the aim of lowering BP, and delaying or even
preventing the progression of diabetic nephropathy.
The reno-protective effects of renin–angiotensin system
(RAS) blockers in type 2 diabetes have been controversial
[8]. A few systematic reviews have been conducted [9–11],
but these reviews pooled studies with mixed populations of
participants with type 1 and type 2 diabetes, with and without
diabetic nephropathy, and the focus was mainly on surrogate
rather than clinical outcomes. We therefore conducted a sys-
tematic review and meta-analysis comparing the effects of
ACE inhibitor (ACEI)/angiotensin II receptor blocker (ARB)
with other antihypertensive drugs and placebo on ESRD,
doubling of serum creatinine, microvascular complications,
micro- and macroalbuminuria and regression of albuminuria.
Methods
Study selection
English-language publications were identified from Medline
(1949–July 2011) and Embase (1974–April 2011) using
PubMed and Ovid search engines. Search terms and strate-
gies for Medline were as follows: (type 2 diabetes or type 2
diabetes mellitus or type 2 DM or non insulin dependent
diabetes) and (ACEI or angiotensin-converting enzyme
inhibitors or ACE inhibitors or ARB or angiotensin receptor
blockers*) and (nephropathy or overt nephropathy or
microalbuminuria or macroalbuminuria or microvascular
complications or doubling serum creatinine or ESRD or
end-stage renal disease or urinary albumin excretion). We
also searched for any additional studies in the reference lists
of identified publications. Data from the most recent or the
most complete report by the same authors were used. We
restricted our searches to clinical trials. Studies with the
following criteria were included: type 2 diabetic adult indi-
viduals, randomised trial comparing any single ACEI/ARB
with other single agents (e.g. beta-blocker [BB], calcium-
channel blocker [CCB], diuretics) or placebo, had at
least one of the following outcomes (microalbuminuria,
macroalbuminuria, albuminuria regression, microvascular
complications, serum creatinine doubling and/or ESRD),
and reported number of patients and events in each
treatment arm. Studies were excluded if they were crossover
trials, used dual therapies or compared different dosages of
ACEI/ARB.
Outcome measures The outcomes of interest were ESRD,
doubling of serum creatinine, microvascular complications,
macroalbuminuria, microalbuminuria and regression of al-
buminuria. ESRD was defined as a requirement for renal
replacement therapy or dialysis. Doubling of serum creati-
nine was defined as an increase in serum creatinine level of
at least two times compared with baseline level. Microvas-
cular complications were defined as a composite of having
nephropathy and/or retinopathy. Microalbuminuria was de-
fined as urine albumin excretion rate of 30–3 0 0m g / 2 4hf o r
24 h urine collection, 3.5–35 mg/mmol for urinary albumin/
creatinineratiofromaspoturinecollection,or20–199μg/min
for timed urine collection. Macroalbuminuria was defined as
urine albumin excretion rate ≥300 mg/24 h, ≥25 mg/mmol
creatinine or ≥200 μg/min for the same specimens, respec-
tively. Regression of albuminuria was defined as a change
from a higher to a lower stage of albuminuria.
Data extraction
Two investigators (P. Vejakama and D. Lertrattananon) in-
dependently extracted data, including study and participant
characteristics (e.g. age, BP, albuminuria stage, serum glu-
cose, and HbA1c) and numbers of events across intervention
groups. Discrepancies were discussed with a third party
(A. Thakkinstian) and resolved by consensus.
Risk of bias assessment
Risk of bias was assessed using the Cochrane Collaboration’s
tool addressing six domains: sequence generation, allocation
concealment, blinding of participants/outcome assessors, in-
complete outcome, selective outcome reporting and other
source of bias. Two investigators (P. Vejakama and
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discrepancies were discussed with a third party (A.Thakkinstian)
and resolved by consensus.
Statistical analysis
For direct meta-analysis, the intervention of interest was
ACEI/ARB monotherapy, while the comparator group was
any antihypertensive drug or placebo. Pooled RRs were
used to compare treatment effects. The Q test and I
2 statistic
were used to assess the presence and degree of heterogeneity.
If heterogeneity was present or I
2 >25%, the random-effects
model was applied, otherwise the fixed-effects model was
used. Sources of heterogeneity were explored using meta-
regression. The Harbord test and a funnel plot were applied
to assess publication bias [12]. If either suggested asym-
metry of the funnel, contour-enhanced funnel plots were
used to distinguish the cause of asymmetry (i.e. heterogeneity
and reporting bias) [13, 14].
A network meta-analysis [15–17] was performed to com-
pare indirectly all treatment effects. Summary data for treat-
ments and outcomes were expanded to the individual patient
level. A binary regression analysis was applied and the
pooled RRs and 95% CIs were estimated. All analyses were
performed using STATA version 11 (Stata Corp., College
Station, TX, USA). p values less than 0.05 were considered
statistically significant, except for the test of heterogeneity
where p<0.10 was used.
Results
Of the 673 articles located, full papers of 153 plus four
additional studies from reference lists were reviewed, leading
to data pooling for 28 studies (see Fig. 1). The characteristics
of these studies are described in Table 1. The major ACEI/
ARBs used were enalapril (32%), followed by lisinopril
(10.7%) and ramipril (10.7%). The majority of comparators
were dihydropyridine CCBs (d-CCBs; 43%), placebo
(39%), or BB/diuretic/non-dihydropyridine CCBs (nd-
CCBs; 18%). Numbers of individuals are summarised
according to the treatments and outcomes of interest
(electronic supplementary material [ESM] Tables 1–6).
The assessments of risk of bias are described in ESM
Table 7. Problems with incomplete outcome reports were
least frequent in 2/28 (7.1%) studies [18, 19], followed by
other sources of bias in 5/28 (17.9%) [18, 20–23] and
selective reporting of outcomes in 5/28 (17.9%) [18, 21,
22, 24, 25]. Although all studies were randomised
controlled trials (RCTs), only 14 (50.0%) studies clearly
described randomisation [21, 25–37] and allocation
concealment [21, 22, 26–29, 31, 33–39].
Direct meta-analysis
ESRD Nine studies [20, 21, 24, 26, 29, 30, 33, 34, 40]
reported the effect of ACEI/ARB on ESRD (n013,295).
Of these, five studies [20, 21, 26, 30, 40] compared ACEI
with other antihypertensive drugs (three BB, two d-CCB),
three [24, 29, 34] compared ACEI with placebo, and one
[33] compared ARB with d-CCB and placebo (ESM
Table 1).
Six studies [20, 21, 26, 30, 33, 40] directly compared
ACEI/ARB with other active drugs (n01,090 vs 1,055);
four were trials that studied patients with macroalbuminuria
whereas the other two studied mixed patients with micro-
and macroalbuminuria.
The treatment effects were homogeneous (χ
201.54, df05,
p00.908, I
200.0%), suggesting that ACEI/ARB reduced the
risk of ESRD by 18% (pooled RR00.82 [95% CI 0.64,
1.05]; see Fig. 2a). However, this result was not statistically
significant (Table 2). Neither the Harbord test nor a funnel
plot (ESM Fig. 1a) suggested publication bias (coefficient
−0.001, SE00.436, p00.998).
For placebo controls, pooled estimates based on four
studies [24, 29, 33, 34]( n05,581 vs 5,569) demonstrated
homogeneous treatment effects (χ
201.11, df03, p00.774,
I
200.0%; Fig. 2b) despite a mix of patients with normo-,
micro- and macroalbuminuria. ACEI/ARB significantly de-
creased the risk of ESRD by 20% (pooled RR00.80 [95%
CI 0.69, 0.93]; Table 2). Although the Harbord test was not
significant (coefficient 1.220, SE00.311, p00.059), the
contour-enhanced funnel plot showed asymmetry (ESM
Fig. 1b). One high-precision study fell in the significant
area (grey shading) whereas the other three (one high and
two low precision) were in the non-significant area.
Applying ‘trim and fill’ suggested two low-precision
studies (square symbols) were missing; adding these
studies yielded a pooled RR of 0.78 (95% CI 0.68, 0.91) with
I
200%.
Doubling of serum creatinine Six studies [20, 24, 29, 33,
34, 39] reported the effect of ACEI/ARB vs other anti-
hypertensive drugs on doubling of serum creatinine
(n016,216), and five studies [24, 29, 33, 34, 39] reported
ACEI/ARB vs placebo (ESM Table 2).
The treatment effects of ACEI/ARB vs antihypertensive
drugs (n0597 vs 601) were homogeneous (χ
200.76, df01,
p00.382, I
200.0%) with a pooled RR of 0.66 (95% CI 0.53,
0.83; Fig. 2b), suggesting a significant reduction in risk of
34%.
The ACEI/ARB effects were also present when com-
pared with placebo (n07,831 vs 7,784). The pooled RR
was 0.76 (95% CI 0.69, 0.84), indicating a 24% lower risk
of serum creatinine doubling. The pooled effect was homo-
geneous (χ
201.67, df04, p00.796, I
200.0%) without
568 Diabetologia (2012) 55:566–578publication bias (Harbord test coefficient00.629, SE00.908,
p00.538; ESM Fig. 2).
Microvascular complications Of five studies [24, 26, 31,
32, 37]( n06,489), only one [26] compared ACEI/ARB
with active drug; the other four [24, 31, 32, 37] compared
ACEI/ARB with placebo (ESM Table 3).
Compared with placebo controls (n02,847 vs 2,884),
ACEI/ARB significantly reduced the risk of microvascular
complications by 15% (pooled RR00.85 [95% CI 0.76,
0.97]), with low heterogeneity (χ
203.34, df03, p00.342,
I
2010.3%; Fig. 2c) and without publication bias (Harbord
test coefficient0−1.51, SE00.53, p00.105; ESM Fig. 3). In
addition,theACEI/ARBgroup(n02,884) had a significantly
lower risk of retinopathy (13% lower, pooled RR00.87
[95% CI 0.76, 0.99]) with low heterogeneity (χ
203.51,
df03, p00.319, I
2014.6%).
Macroalbuminuria Twelve studies [19, 21–26, 32, 36, 38,
41, 42] reported ACEI/ARB effects on macroalbuminuria
(n05,151) with ACEI/ARB vs other therapies (five with
d-CCB, one with diuretic, one with BB and one with BB/
diuretic) in eight studies [19, 21–23, 25, 26, 36, 38] and
placebo in five studies [24, 32, 36, 41, 42] (ESM Table 4).
Eight trials [19, 22, 25, 26, 32, 36, 38, 41]( n01,401)
studied patients with microalbuminuria, and four [21, 23,
24, 42]( n03,761) studied mixed patients with normo- and
microalbuminuria.
Direct pooled estimates of treatment effects between
ACEI/ARB and other antihypertensive drugs (n0641 vs
304 studies identified from 
Medline 
369 studied identified from 
Embase 
4 studies identified 
from reference
516 titles/abstracts evaluation 
153 full papers were reviewed 
28 studies included in the review 
and data extraction   
157 duplicates removed 
367 studies excluded: reasons for exclusion were
-138 non-RCTs  
-119 non-ACEI/ARB interventions 
-49 no outcome of interest
-43 non-type 2 diabetic participants
-10 non-active drugs/placebo comparators 
-3 non-available abstracts
-3 ACEI/ARB comparators 
-2 cross-over design
125 studies excluded: reasons for exclusion were 
-56 no outcome of interest
-26 duplicated reports 
-14 non-RCTs 
-6 non-type 2 diabetic participants 
-6 non-active drugs/placebo comparators 
-6 non-English papers
-5 cross-over design
-3 non-ACEI/ARB interventions
-3 ACEI/ARB comparator 
18 studies compared ACEI/ARB vs active drugs  
(31 comparisons) for the following outcomes
-6 ESRD
-2 doubling of serum creatinine
-1 major microvascular complications 
-8 macroalbuminuria 
-6 microalbuminuria 
-9 regression of albuminuria
13 studies compared ACEI/ARB vs placebo 
(20 comparisons) for the following outcomes
-4 ESRD
-5 doubling of serum creatinine
-4 major microvascular complications
-5 macroalbuminuria
-4 microalbuminuria
-2 regression of albuminuria
Fig. 1 Flow of study selection
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Authors [ref.] RR (95% CI) treatment control Weight (%)
Active drugs
Bakris et al [20] 0.20 (0.01, 3.60) 0/18 4/34 0.73
Nielsen et al [30] 1.12 (0.08, 16.52) 1/17 1/19 0.83
UKPDS [26] 0.89 (0.23, 3.55) 4/400 4/358 3.16
0.81 1/25 1/26 0.96 (0.06, 14.55) Fogari et al [40]
4.78 5/52 6/50 1.25 (0.41, 3.83) Chan et al [21]
89.69 106/567 87/579 0.80 (0.62, 1.04) Lewis et al [33]
100.00 121/1,055 99/1,090 0.82 (0.64, 1.05) Pooled RR (I2= 0.0%)
.
Placebo
2.56 8/1,769 10/1,808 1.22 (0.48, 3.09) HOPE [24]
61.48 194/762 147/751 0.77 (0.64, 0.93) Brenner et al [34]
32.66 105/569 87/579 0.81 (0.63, 1.06) Lewis et al [33]
3.30 12/2,469 1/2,443 0.93 (0.41, 2.10) Marre et al [29]
100.00 319/5,569 255/5,581 0.80 (0.69, 0.93) Pooled RR (I2= 0.0%)
.
1 1 3 10 1 0.01 0.5
Favour treatment Favour control RR
b Events Events
Authors [ref.] RR (95% CI) control Weight (%) treatment
Active drugs
0.27 (0.04, 2.03) 7/34 1.27 1/18 Bakris et al [20]
144/567 98.73 98/579 Lewis et al [33] 0.67 (0.53, 0.84)
100.00 151/601 0.66 (0.52, 0.83) Pooled RR (I2= 0.0%) 99/597
.
Placebo
149/1,769 23.91 118/1,808 HOPE [24] 0.77 (0.61, 0.98)
198/762 162/751 Brenner et al [34] 0.83 (0.69, 1.00) 39.20
23.81 135/569 0.71 (0.57, 0.90) Lewis et al [33] 98/579
9.17 60/2,469 0.81 (0.56, 1.18) Marre et al [29] 48/2,443
Haller et al [39] 0.99 (0.56, 1.76)  23/2,215 3.91 23/2,232
565/7,784 100.00 449/7,813 Pooled RR (I2= 0.0%) 0.79 (0.71, 0.89)
.
1 0.03 0.5 3 5
RR Favour treatment Favour control
Events Events
Authors [ref.] treatment control Weight (%) RR (95% CI)
Ravid et al [32] 0.64 (0.30, 1.34) 9/49 13/45 3.09
Ravid et al [31] 0.41 (0.17, 1.00) 6/77 15/79 2.17
HOPE [24] 0.86 (0.74, 0.99) 
Sjolie et al [37] 0.89 (0.73, 1.08) 
273/1,808 312/1,769 56.49
161/950 182/954 38.24
100.00 522/2,847 449/2,884 0.85 (0.74, 0.97) Pooled RR (I2= 10.3%)
1 0.15 0.5 1 1.3
RR Favour treatment Favour control
c
Fig. 2 Forest plots of treatment effects between ACEIs and other active drugs: (a) ESRD; (b) doubling of serum creatinine; (c) major
microvascular complications; (d) macroalbuminuria; (e) microalbuminuria; and (f) albuminuria regression
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Authors [ref.]
Events Events
RR (95% CI) treatment control Weight (%)
Active drugs
1.41 2/12 0/9 0.26 (0.01, 4.83) Lacourciere et al [22]
UKPDS [26] 0.48 (0.20, 1.15) 7/153 14/146 15.60
Chan et al [21] 0.65 (0.20, 2.12) 4/39 6/38 8.59
Estacio et al [19] 0.95 (0.50, 1.81) 13/67 17/83 28.81
Shiba et al [23] 0.08 (0.00, 1.37) 0/23 4/16 1.48
Baba et al [25]
Marre et al [38]
0.91 (0.21, 3.87)
0.69 (0.38, 1.22) 
3/53
18/286
4/64
26/283
5.71
36.03
Jerums et al [36] 2.00 (0.21, 18.98) 2/11 1/11 2.38
100.00 74/653 47/641 0.70 (0.50, 1.00) Pooled RR (I2= 0.0%)
.
Placebo
Ravid et al [32] 0.29 (0.13, 0.66) 6/49 19/45 21.92
Lebovetz et al [42] 0.32 (0.07, 1.38) 2/30 8/38 10.79
Ahmad et al [41] 0.33 (0.11, 0.95) 4/52 12/51 16.70
HOPE [24] 0.77 (0.61, 0.97) 117/1,808 149/1,769 38.54
Jerums et al [36]
Pooled RR (I2 = 53.7%)
0.39 (0.10, 1.53)
0.45 (0.26, 0.79) 
2/11
131/1,950
7/15
195/1,918
12.05
100.00
.
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Events Events
Authors [ref.] RR (95% CI) treatment control Weight (%)
Active drugs
Lacourciere et al [22] 0.56 (0.05, 5.81) 1/25 2/28 1.74
UKPDS [26] 1.21 (0.84, 1.73) 48/153 38/146 30.58
Chan et al [21] 1.11 (0.35, 3.57) 4/18 5/25 6.35
Estacio et al [19] 0.87 (0.53, 1.42) 25/123 25/107 22.79
Baba et al [25] 0.73 (0.40, 1.31) 15/95 23/106 18.30
Ruggenenti et al [43] 0.50 (0.29, 0.87) 18/301 36/303 20.24
Pooled RR (I2= 35.1%) 0.84 (0.61, 1.15) 111/715 129/715 100.00
.
Placebo
5/77 0.34 (0.13, 0.90) Ravid et al [31]
Ruggenenti et al [43] 18/301 0.60 (0.34, 1.05)
114/951 0.92 (0.73, 1.17) Bilous et al [35]
178/1961 0.92 (0.76, 1.12) Haller et al [39]
315/3290 0.82 (0.64, 1.05) Pooled RR (I2=49.4%)
15/79 5.87
30/300 14.35
124/954 37.21
210/2139 42.58
379/3472 100.00
.
1 0.054 1 18.5
RR Favour treatment Favour control
e
Events Events
Authors [ref.] control Weight (%) RR (95% CI) treatment
Active drugs
Mosconi et al [44] 4/7 3.88 1.17 (0.50, 2.74) 4/6
Chan et al [21] 5/27 2.51 1.01 (0.35, 2.95) 6/32
Baba et al [25] 19/64 6.62 0.70 (0.37, 1.34) 11/53
Fogari et al [28] 34/103 20.34 1.40 (0.99, 1.97) 47/102
Jerums et al [36 3/11 0.66 0.33 (0.04, 2.73) 1/11
Marre et al [38] 112/283 45.91 1.06 (0.87, 1.29) 120/286
Fogari et al [27] 19/50 13.73 1.45 (0.94, 2.24) 27/49
Kashiwagi [18] 9/77 5.11 1.99 (0.95, 4.18) 17/73
Ogawa et al [45] 2/18 1.23 1.32 (0.28, 6.16) 5/34
Pooled RR (I2= 8.4%) 207/640 100.00 1.17 (0.99, 1.39) 238/646
.
Placebo
Jerums et al [36] 3/15 0.55 0.45 (0.05, 3.81) 1/11
Marre et al [38] 215/933 99 1.17 (1.00, 1.37) 253/936
Pooled RR (I2= 0.0%) 218/948 100.00 1.17 (1.00, 1.37) 254/947
.
1 0.03 0.5 1 2 4 6 1
f
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Fig. 2 (continued)
Diabetologia (2012) 55:566–578 573653) of eight trials [19, 21–23, 25, 26, 36, 38] were homo-
geneous (χ
205.24, df07, p00.631, I
200.0%; Fig. 2d) with
borderline significant risk reduction of 29% (pooled RR0
0.71 [95% CI 0.50, 1.00]). Neither the Harbord test nor the
funnel plot suggested publication bias (coefficient0−0.733,
SE00.828, p00.410; ESM Fig. 4a).
Among five placebo-controlled trials [24, 32, 36, 41, 42]
(n01,950 vs 1,918), the pooled RR was 0.45 (95% CI 0.26,
0.79) with moderate heterogeneity (χ
208.64, df04,
p00.071, I
2053.7%; Fig. 2d). This suggested that ACEI/
ARB significantly reduced risk of macroalbuminuria by 55%.
The Harbord test suggested asymmetry of the funnel plot
(coefficient0−2.043, SE00.547, p00.033). The contour-
enhanced funnel plot showed that one-half of the studies
included were in the high- and non-significance areas (ESM
Fig. 4b), suggesting treatment-effect heterogeneity. Meta-
regression analysis fitting type of patient (microalbumi-
nuria and mixed patients) reduced the degree of hetero-
geneity (I
2) from 53.7% to 0%. Subgroup analysis
performed in patients with microalbuminuria and mixed
micro- and macroalbuminuria yielded pooled RRs of 0.31
(95% CI 0.18, 0.57) and 0.45 (95% CI 0.26, 0.79),
respectively.
Microalbuminuria Nine studies [19, 21, 22, 25, 26, 31, 35,
39, 43] had microalbuminuria outcomes (n07,891): six [19,
21, 22, 25, 26, 43] looking at ACEI vs other antihypertensive
drugs, two looking at ACEI vs placebo [31, 43] and two
looking at ARB vs placebo [35, 39] (ESM Table 5).
The pooled treatment effects between ACEI/ARB
and other antihypertensive drugs were somewhat
heterogeneous (χ
207.70, df05, p00.174, I
2035.1%) with
a pooled RR of 0.84 (95% CI 0.61, 1.15) (Table 2 and
Fig. 2e). The Harbord test suggested no asymmetry of
the funnel plot (coefficient0−0.281, SE01.367, p00.847;
ESM Fig. 5a).
Compared with placebo in four studies [31, 35, 39,
43]( n03,290 vs 3,472), the pooled effect of ACEI/ARBs
[24, 28, 32, 37] was 0.82 (95% CI 0.64, 1.05; Fig. 2e)
with moderate heterogeneity (χ
205.93, df03, p00.115,
I
2049.4%). Meta-regression could not identify the source
of the heterogeneity. The Harbord test suggested asymmetry
of the funnel (coefficient0−2.626, SE00.360, p00.018),
and the contour-enhanced funnel plot suggested that this
heterogeneity might be the cause of the asymmetry (ESM
Fig. 5b).
Albuminuria regression Ten studies [18, 21, 25, 27–29, 36,
38, 44, 45] reported regression of albuminuria (n03,710;
ESM Table 6).
The treatment effect between ACEI/ARB and other anti-
hypertensive drugs, based on nine studies [18, 21, 25, 27,
28, 36, 38, 44, 45]( n0646 vs 640), was homogeneous
(χ
208.74, df08, p00.365, I
208.4%) with a borderline
non-significant effect of 16% (pooled RR01.16 [95% CI
0.99, 1.39]; see Table 2 and Fig. 2f). Neither the Harbord
test nor a funnel plot suggested publication bias (coef-
ficient0−0.086, SE00.718, p00.907; ESM Fig. 6).
Table 2 Summarised character-
istics of studies and direct pool-
ing treatment effects according
to clinical outcomes
Dichotomous outcomes Number of studies Sample size RR (95% CI)
ESRD
ACEI/ARB vs other active drugs 6 2,147 0.82 (0.64, 1.05)
ACEI/ARB vs placebo 4 10,581 0.80 (0.69, 0.93)
Doubling of serum creatinine
ACEI/ARB vs other active drugs 2 1,198 0.66 (0.53, 0.83)
ACEI/ARB vs placebo 4 10,594 0.76 (0.69, 0.84)
Major microvascular complications
ACEI/ARB vs other active drugs 1 758 1.28 (0.81, 2.03)
ACEI/ARB vs placebo 4 6,489 0.85 (0.74, 0.97)
Macroalbuminuria
ACEI/ARB vs other active drugs 8 1,211 0.71 (0.50, 1.00)
ACEI/ARB vs placebo 5 3,868 0.67 (0.54, 0.83)
Microalbuminuria
ACEI/ARB vs other active drugs 6 1,430 0.84 (0.61, 1.15)
ACEI/ARB vs placebo 4 6,762 0.82 (0.64, 1.05)
Albuminuria regression
ACEI/ARB vs other active drugs 9 1,286 1.16 (0.99, 1.39)
ACEI/ARB vs placebo 2 1,238 1.17 (1.00, 1.37)
574 Diabetologia (2012) 55:566–578For the placebo-controlled trials (n0947 vs 948), the
likelihood of albuminuria regression was 17% higher with
ACEI/ARB, which was on the borderline of non-significance
(RR01.17 [95% CI 1.00, 1.37]; Table 2).
Network meta-analysis
ESRD A network meta-analysis was applied to assess all treat-
ment comparisons, (ESM Fig. 7a and ESM Table 8). Arrows
and tails refer to interventions and comparators, bold and
dashed lines refer to direct and indirect comparisons, respec-
tively. Numbers under the line refer to the number of studies
for the direct comparator data, whereas numbers above the
line indicate pooled RRs. The analysis suggested that the
ACEI/ARB (n06,092) significantly decreased the risk of
ESRD when compared with d-CCB (n0644) and placebo
(n05,569,) with pooled RRs of 0.25 (95% CI 0.07, 0.96)
and 0.77 (95% CI 0.64, 0.92), respectively. However, the
risk of ESRD was 2.00 (95% CI 0.35, 11.55) times higher,
but not significantly so, compared with the BB group
(n0411). Comparing ACEI/ARB with all antihypertensive
drugs (dCCB + BB) resulted in 62% significantly lower risk
of ESRD (pooled RR00.38 [95% CI 0.31, 0.47]).
Pooling mean BPs from four studies [21, 26, 30, 40]
showed non-significant differences between groups, with
mean differences of 1.27 (95% CI −1.42, 3.95) for systolic
BP (SBP) and −0.71 (95% CI −3.88, 2.46) for diastolic BP
(DBP).
Doubling of serum creatinine ESMFig.7b and ESM Table 8
show that ACEI/ARBs (n07,831) significantly reduced the
risk of serum creatinine doubling by 77% (pooled RR00.23
[95% CI 0.09, 0.57]), 72% (pooled RR00.28 [95% CI 0.11,
0.71]), and 21% (pooled RR00.79 [95% CI 0.75, 0.84])
compared with d-CCB (n0567), nd-CCB/BB (n034), and
placebo (n07,784), respectively. Combining all antihyper-
tensive drugs (n0601) and comparing with ACEI/ARB
resulted in 77% significantly lower risk (pooled RR00.23
[95% CI 0.09, 0.58]).
Microvascular complications The number of participants in
each treatment arm is described in ESM Table 3, with total
number of patients in ACEI/ARB and placebo of 3,284 vs
2,847, respectively. ACEI/ARBs significantly reduced the
risk of microvascular complications by 19% (pooled RR0
0.81 [95% CI 0.71, 0.92]) when compared with placebo, but
increased the risk almost twofold when compared with BB
(ESM Fig. 7c and ESM Table 8).
Macroalbuminuria Network meta-analysis was performed
based on 12 studies [19, 21–26, 32, 36, 38, 41, 42]
(n05,151; ESM Table 4). ACEI/ARBs (n02,580) signifi-
cantly reduced macroalbuminuria by 29% (pooled RR00.71
[95% CI 0.62, 0.83]) compared with BB/diuretic (n0441),
55% (pooled RR00.45 [95% CI 0.29, 0.70]) vs d-CCB
(n0212), and 33% (pooled RR00.67 [95% CI 0.49, 0.92])
vs placebo (n01,918; ESM Fig. 7d and ESM Table 8). The
ACEI/ARBs significantly reduced macroalbuminuria by
40% (pooled RR00.60 [95% CI 0.47, 0.77]) compared with
all antihypertensive drugs (n0653).
Pooling SBP and DBP in three studies [21, 38, 41], the
mean SBP and DBP differences were 2.82 (95% CI 0.32,
5.31) and 0.33 (95% CI −0.93, 1.60) mmHg, respectively.
Microalbuminuria Based on pooling of results from nine
studies [19, 21, 22, 25, 26, 31, 35, 39, 43]( n07,891), ACEI/
ARB (n03,704) had significantly better benefit than d-CCB
(n0238) with a pooled RR of 0.50 (95% CI 0.38, 0.65), but
significantly worse outcomes than BB (i.e. favouring BB )
with the pooled RR of 0.48 (95% CI 0.35, 0.66; ESM
Fig. 7e and ESM Table 8). When compared with nd-CCB
(n0303) and placebo (n03,472), ACEI/ARBs did not re-
duce microalbuminuria with pooled RRs of 0.93 (95% CI
0.71, 1.22) and 1.01 (95% CI 0.82, 1.25), respectively.
Compared with all antihypertensive drugs, the ACEI/ARB
significantly reduced the risk by 39% (pooled RR00.61
[95% CI 0.45, 0.83]).
Regression of albuminuria Using data from ten studies
(n03,710) [18, 21, 25, 27–29, 36, 38, 44, 45], ACEI/ARB
(n01,582) significantly promoted regression of albuminuria
compared with placebo (n0948), but not with diuretic
(n0283); RRs were 1.35 (95% CI 1.07, 1.70) in favour of
ACEI/ARB and 1.28 (95% CI 1.02, 1.60) in favour of
diuretic, respectively (ESM Fig. 7f and ESM Table 8). The
pooled RR was1.16 (95% CI 0.83, 1.63) for ACEI/ARB vs
d-CCB (n0357).
In six of ten studies where data were available [21, 27–29,
44, 45], the mean SBP was significantly higher for ACEI/
ARB (mean difference02.35 [95% CI 1.07, 3.64]) than
placebo but not so for DBP (mean difference00.54 mmHg
[95% CI −0.40, 1.48 mmHg]).
Discussion
The direct and indirect comparisons in our study confirm the
clear benefit of ACEI/ARB over placebo for all outcomes
(ESRD, serum creatinine doubling, microvascular compli-
cations, macroalbuminuria and regression of albuminuria)
exceptmicroalbuminuria.Thelackofastatisticallysignificant
treatment effect for microalbuminuria outcome is likely to
result partly from the heterogeneity of treatment effects across
the studies.
Our study extends the results of Strippoli et al. [11], who
showed borderline significant benefit for ACEI/ARB vs
Diabetologia (2012) 55:566–578 575placebo for doubling of serum creatinine (RR=0.79 [95%
CI 0.75, 0.84] vs 0.60 [95% CI 0.34, 1.05]) and ESRD
(RR=0.77 [95% CI 0.64, 0.92] vs 0.64 [95% CI 0.4, 1.03]).
Theadditionofnewdataandtheuseofnetworkmeta-analysis
methods increase the power and allow us to demonstrate the
reno-protective effects of RAS blockade more confidently.
The major contribution of our study is in teasing out the
potential reno-protective effect of ACEI/ARBs over other
antihypertensive drugs. Overall, the direct meta-analysis
suggests a potential benefit of ACEI/ARB in reducing
macroalbuminuria and doubling of serum creatinine, and
in promoting regression of albuminuria. The results of
network meta-analysis suggest additional benefits of the
ACEI/ARB in reducing the risk of ESRD. These benefits
contradict the previous meta-analysis [9], which found reno-
protective effects of ACEI/ARB in patients without diabetes
but not in patients who had already developed diabetic
nephropathy. This discrepancy with previous work may be
due partly to the addition of new data, thereby improving
power, or may be driven partly by the fact that the major
active comparators were CCBs; in some comparisons, BBs
anddiureticsaresignificantlybetterthanACEI/ARBs,though
the numbers inthese comparisons are small and drivenlargely
by the UK Prospective Diabetes Study (UKPDS).
In the studies that reported BP change, there was no
significant difference in BP decrease between ACEI/ARB
and other antihypertensive drugs, suggesting that there is a
specific reno-protective effect of ACEI/ARBs beyond their
antihypertensive effect. This runs contrary to the conclusion
of Casas et al. [9], who found the effect of RAS blockade to
depend on its BP-lowering effect. In their study, Casas et al.
showed that the benefit of RAS blockers compared with
active control was associated with the extra degree of BP
decrease. These results are hard to reconcile with summary-
level data. It is of course possible for both conclusions to be
true, i.e. the effect of RAS blockers is linked to the level of
BP control but that for two agents that bring about the same
drop in BP, RAS blockers would have an additional benefit.
This possibility would be better teased out with a meta-
analysis of individual patient data or a direct test of this
hypothesis in a large-scale RCT.
Our study has some strengths. We have applied a network
meta-analysis to increase the power of the tests and reduce
type I errors [15–17]. We applied a mixed model, which is
thought to be the most appropriate method for this kind of
pooling. The network method ‘borrows’ treatment informa-
tion from other studies and increases the total sample size.
As a result, treatment effects that could not be detected or
treatment effects of borderline significance in direct meta-
analysis could be identified. In addition, all possible treat-
ment comparisons are mapped and displayed (see ESM
Table 9). The weakness of our study is that despite the large
overall numbers, some comparator groups still have small
numbers, leading to poor precision of estimates. The lack of
BP data for some studies also limits our ability to judge the
specific reno-protective effects.
In conclusion, there appears to be a consistent benefit of
ACEI/ARB on all outcomes in type 2 diabetes, including the
‘hard clinical endpoints’ of ESRD and doubling of serum
creatinine, when compared with other antihypertensive
drugs (mainly CCBs) and placebo, both in direct and indirect
meta-analyses. This is seen in the context of no difference in
BP decrease, suggesting a specific reno-protective effect.
Other antihypertensives, particularly BBs and diuretics, may
have even greater reno-protective effects but this needs
to be investigated in further studies or individual patient
meta-analysis.
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